MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

FibroGen Company Profile (NASDAQ:FGEN)

Consensus Ratings for FibroGen (NASDAQ:FGEN) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $33.50 (81.77% upside)

Analysts' Ratings History for FibroGen (NASDAQ:FGEN)
Show:
DateFirmActionRatingPrice TargetActions
5/25/2016Credit SuisseReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman SachsLower Price Target$34.00 -> $31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/29/2015Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2015Citigroup Inc.Initiated CoverageBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/23/2015Lake Street CapitalInitiated CoverageHold$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014Stifel NicolausInitiated CoverageBuy$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014RBC CapitalInitiated CoverageOutperform$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2014William BlairInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/28/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha